Romosozumab-Aqqg
Brand name: Evenity (2 Syringes)
Rank #399 of 500 drugs by total cost
$22.3M
Total Cost
9,087
Total Claims
$22.3M
Total Cost
304
Prescribers
$2,449
Cost per Claim
771
Beneficiaries
9,252
30-Day Fills
$73K
Avg Cost/Provider
30
Avg Claims/Provider
About Romosozumab-Aqqg
Romosozumab-Aqqg (sold as Evenity (2 Syringes)) was prescribed 9,087 times by 304 Medicare Part D providers in 2023, costing the program $22.3M. At $2,449 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 396 | Fenofibrate Nanocrystallized (Fenofibrate) | $23.2M | 602,181 |
| 397 | Ravulizumab-Cwvz (Ultomiris) | $23.1M | 428 |
| 398 | Roflumilast (Roflumilast) | $22.8M | 97,022 |
| 399 | Romosozumab-Aqqg (Evenity (2 Syringes)) | $22.3M | 9,087 |
| 400 | Azithromycin (Azithromycin) | $22.2M | 3,009,458 |
| 401 | Torsemide (Torsemide) | $22.2M | 971,579 |
| 402 | Doxepin Hcl (Doxepin Hcl) | $22.2M | 371,255 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology